Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

In 2025, Aetna will merge its three stand-alone prescription drug plans into a single plan and member cost-shares will be ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...

Reference ustekinumab was originally approved by the FDA in 2009. Wezlana (ustekinumab-auub) was approved last October.